RUTI - Archivel Farma
Alternative Names: RUTILatest Information Update: 28 Jan 2025
At a glance
- Originator Archivel Farma
- Developer Archivel Farma; London School of Hygiene & Tropical Medicine; RUTI Immunotherapeutics
- Class Antineoplastics; Cancer vaccines; COVID-19 vaccines; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections; Tuberculosis
- No development reported Allergic rhinitis; Asthma; Bladder cancer
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Bladder-cancer(Prevention) in Spain (SC, Liposomal)
- 28 Dec 2024 No recent reports of development identified for phase-I development in Allergic-rhinitis in Spain (SC, Liposomal)
- 28 Dec 2024 No recent reports of development identified for phase-I development in Asthma in Spain (SC, Liposomal)